Candel Therapeutics (CADL) Cash from Investing Activities (2020 - 2025)
Candel Therapeutics (CADL) reported Cash from Investing Activities of -$409000.0 for Q4 2025, down 13533.33% on a YoY basis from N/an in Q4 2024, and down 249.57% sequentially from -$117000.0 in Q3 2025.
Candel Therapeutics (CADL) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Cash from Investing Activities data on file, last reported at -$409000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities fell 13533.33% year-over-year to -$409000.0; the trailing twelve-month figure through Dec 2025 stood at -$560000.0 (down 3400.0% YoY), and the FY2025 full-year result was -$560000.0, down 3400.0% from the prior year.
- Cash from Investing Activities slipped to -$409000.0 in Q4 2025, from -$117000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $19000.0 in Q1 2023 to a low of -$710000.0 in Q2 2021.
- A 5-year average of -$209894.7 and a median of -$169000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 111.11% in 2023 and plunged 13533.33% in 2025, its largest moves.
- Tracing CADL's Cash from Investing Activities over 5 years: stood at -$504000.0 in 2021, then surged by 45.24% to -$276000.0 in 2022, then soared by 90.22% to -$27000.0 in 2023, then soared by 88.89% to -$3000.0 in 2024, then sank by 13533.33% to -$409000.0 in 2025.
- Business Quant data shows CADL's Cash from Investing Activities at -$409000.0 in Q4 2025, -$117000.0 in Q3 2025, and -$31000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Candel Therapeutics | 530.65 Mn | 530.65 Mn | - | -409,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -409,000.00 |
| Dec 31, 2025 | -409,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Sep 30, 2023 | -103,000.00 |
| Sep 30, 2023 | -103,000.00 |
| Jun 30, 2023 | -169,000.00 |
| Jun 30, 2023 | -169,000.00 |